Established indications for<unk>  as first-line treatment (either alone or in conjunction with other agents)
Guillain-Barre syndrome
Thrombotic thrombocytopenic purpura
Myasthenia gravis
Hyperviscosity syndrome
Diffuse alveolar hemorrhage due to Goodpasture syndrome
Chronic inflammatory demyelinating polyneuropathy
Severe autoimmune hemolytic anemia
Indications for which<unk>  is accepted second-line therapy:
Lambert-Eaton myasthenic syndrome
Multiple sclerosis: acute CNS demyelination unresponsive to steroids
Rapidly progressive vasculitis
Catastrophic thrombosis due to antiphospholipid syndrome
Acute disseminated encephalomyelitis
Severe systemic lupus erythematosus
Multiple myeloma cast nephropathy
RBC alloimmunization in pregnancy
Mushroom Poisoning
Hemolytic uremic syndrome
Less established, possible indications
Thyroid storm when antithyroid drugs ineffective or contraindicated
Pemphigus vulgaris (severe and refractory to first-line management)
Pyoderma gangrenosum
Guillain-Barre syndrome
Thrombotic thrombocytopenic purpura
Myasthenia gravis
Hyperviscosity syndrome
Diffuse alveolar hemorrhage due to Goodpasture syndrome
Chronic inflammatory demyelinating polyneuropathy
Severe autoimmune hemolytic anemia
Lambert-Eaton myasthenic syndrome
Multiple sclerosis: acute CNS demyelination unresponsive to steroids
Rapidly progressive vasculitis
Catastrophic thrombosis due to antiphospholipid syndrome
Acute disseminated encephalomyelitis
Severe systemic lupus erythematosus
Multiple myeloma cast nephropathy
RBC alloimmunization in pregnancy
Mushroom Poisoning
Hemolytic uremic syndrome
Thyroid storm when antithyroid drugs ineffective or contraindicated
Pemphigus vulgaris (severe and refractory to first-line management)
Pyoderma gangrenosum
Plasmapheresis
Exchange transfusion
Intravenous immunoglobulin
Extracorporeal membrane oxygenation
Iridodialysis
Platelet transfusion
Cyclopentolate
Massive transfusion 